Ignite Creation Date:
2024-05-05 @ 12:11 PM
Last Modification Date:
2024-10-26 @ 9:21 AM
Study NCT ID:
NCT00262847
Status:
COMPLETED
Last Update Posted:
2019-07-23
First Post:
2005-12-06
Brief Title:
Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial Primary Peritoneal or Fallopian Tube Cancer
Sponsor:
National Cancer Institute NCI
Organization:
National Cancer Institute NCI
Conditions & Keywords Data
Conditions:
| Name |
|---|
| Undifferentiated Ovarian Carcinoma |
| Fallopian Tube Clear Cell Adenocarcinoma |
| Fallopian Tube Endometrioid Adenocarcinoma |
| Fallopian Tube Mucinous Adenocarcinoma |
| Fallopian Tube Serous Adenocarcinoma |
| Fallopian Tube Transitional Cell Carcinoma |
| Malignant Ovarian Mixed Epithelial Tumor |
| Ovarian Brenner Tumor |
| Ovarian Clear Cell Adenocarcinoma |
| Ovarian Endometrioid Adenocarcinoma |
| Ovarian Mucinous Adenocarcinoma |
| Ovarian Serous Adenocarcinoma |
| Ovarian Transitional Cell Carcinoma |
| Primary Peritoneal Serous Adenocarcinoma |
| Stage IIIA Fallopian Tube Cancer |
| Stage IIIA Ovarian Cancer |
| Stage IIIA Primary Peritoneal Cancer |
| Stage IIIB Fallopian Tube Cancer |
| Stage IIIB Ovarian Cancer |
| Stage IIIB Primary Peritoneal Cancer |
| Stage IIIC Fallopian Tube Cancer |
| Stage IIIC Ovarian Cancer |
| Stage IIIC Primary Peritoneal Cancer |
| Stage IV Fallopian Tube Cancer |
| Stage IV Ovarian Cancer |
| Stage IV Primary Peritoneal Cancer |
| Undifferentiated Fallopian Tube Carcinoma |
Keywords: